The February 2024 versions of SF 85, 85P, 85P-S, and 86 are now required for all background investigations. Earlier forms are no longer accepted by DCSA.

New BIS Affiliates Rule: Foreign entities 50%+ owned by listed parties now face automatic export restrictions. Ownership, not just listing, triggers controls.

Omnicare’s Bankruptcy After a Near-$1b FCA Judgment: What Pharmacies, LTC Operators, and PBMs Need To Do Now

GLP-1 weight-loss drugs like semaglutide and tirzepatide face increased regulatory and legal scrutiny. Providers must follow compliance, use FDA-approved drugs, document thoroughly, and ensure HIPAA adherence to minimize liability.

Learn how NY Medicaid providers can use OMIG audit protocols to stay compliant, reduce audit risk, and protect against repayment demands.

MDRXLaw secures $7 million arbitration victory, setting a precedent for pharmacy reimbursement fairness.

2026 CMS Rule updates RPM billing, enhancing provider flexibility and patient access.

Pharmacies risk legal exposure by using consultants for audits. Attorney-client privilege, legal strategy, and representation are critical in PBM investigations.

DOJ and HHS relaunch FCA task force, signaling stricter, proactive healthcare fraud enforcement—Medicare Advantage, kickbacks, and data analytics in focus.

Pharmacies face rising audits and legal risks for false prior authorizations. Protect now.

NY pharmacies can use CoverMyMeds for Medicaid ePAs starting summer 2025. Learn how to stay compliant and streamline approvals with expert legal guidance.

Proudly recognized in the Chambers Spotlight New York 2025 Guide, MDRXLaw continues to set the standard for excellence in healthcare law.